GlaxoSmithKline Granted European Approval for Lung Cancer Drug
Posted on: Tuesday, 13 May 2008, 09:01 CDT
GlaxoSmithKline has announced that oral Hycamtin has received approval from the European Commission, for the treatment of patients with relapsed small cell lung cancer for whom re-treatment with the first-line regimen is not considered appropriate.
The approval was based on positive results from a Phase III study comparing topotecan hard capsules plus best supportive care (BSC ) to BSC alone in patients with relapsed small cell lung cancer (SCLC), in addition to Phase II and Phase III supporting studies.
Eddie Gray, president, pharmaceuticals Europe, GlaxoSmithKline (GSK), said: "Topotecan hard capsules provide physicians and patients with an alternative, effective treatment, with the added convenience of being administered orally."
Source: Datamonitor
Related Articles
- CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina
- Neurocrine Completes Treatment Phase for Endometriosis Study
- Neurocrine Biosciences Completes 'Petal Study' Treatment Phase for Endometriosis
- Data Presented at This Year's ASCO Meeting Provide New Insights into the Treatment of Patients With Myelodysplastic Syndromes
- Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
- CORRECTING and REPLACING Columbia Laboratories Completes Treatment Phase of Phase III Study of PROCHIEVE 8% to Prevent Recurrent Preterm Birth
- Columbia Laboratories Completes Treatment Phase of Phase III Study of PROCHIEVE 8% to Prevent Recurrent Preterm Birth
- New Treatment Guidelines Support Use of FUZEON(R) to Achieve Undetectable HIV in Treatment-Experienced Patients
- Cytomedix Completes Treatment Phase of Clinical Trial For Diabetic Foot Ulcers
- Results of Phase IIa Study Show That Reverset Has Potential to Reduce HIV Viral Load in Treatment-Experienced Patients
User Comments (0)
RSS Feeds